Small Biotechs Spending Less

Inside BIO Industry Analysis

The median and mean operational cash spending for small public US biotechs (less than 250 employees) is down 37% and 42% respectively, since the 1st Quarter of 2008. Company cut backs have shown up in the lay-off numbers as well as in the number of drug development projects put on hold.

These quarterly numbers give a sense of the direction. For a look at the annual data, here is how spending breaks down for the last 12 months ending 3Q09:

68% of small biotechs spent above $5M / year

33% of small biotechs spent above $10M / year

12% of small biotechs spent more than $40M / year

Inside BIO Industry Analysis  |  Email This Post  |  Printer Friendly
Tags: , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>